%I American Medical Association
%L discovery10205615
%C United States
%A Gianmarco Leone
%A Francesco Orlando
%A Peter Dutey-Magni
%A Osvaldas Vainauskas
%A Emily Grist
%A Yari Ciani
%A Sharanpreet Lall
%A Suparna Thakali
%A Anna Wingate
%A Daniel Wetterskog
%A Ashwin Sachdeva
%A Matthew R Sydes
%A Neil McPhail
%A Thiagarajan Sreenivasan
%A Joe M O'Sullivan
%A Noel W Clarke
%A Mahesh KB Parmar
%A Louise C Brown
%A Nicholas D James
%A Francesca Demichelis
%A Gerhardt Attard
%A the STAMPEDE collaborators
%T Plasma AR Alterations and Timing of Intensified Hormone Treatment for Prostate Cancer:
the STAMPEDE Phase 3 Randomized Clinical Trial
%J JAMA Oncology
%X We previously reported that abiraterone acetate and prednisolone (hereafter abiraterone) added at initiation of androgen deprivation therapy (ADT) improved survival of metastatic and very high-risk locally advanced prostate cancer and that combining with enzalutamide did not change efficacy.1 Using next-generation sequencing on plasma DNA, we previously showed that genomic alterations of the androgen receptor (AR) gene contribute to resistance to abiraterone or enzalutamide when initiated for metastatic castration-resistant prostate cancer after progression with ADT alone.2 It is unknown whether hormone intensification at start of ADT alters selection of AR alterations within the gene body and/or enhancer region.3
%O This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
%D 2025